ReviewBrain sciences2021
Melatonin: From Neurobiology to Treatment.
Review in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Melatonin Bioavailability After Oral Administration of a New Delayed-Release Form in Healthy Male Volunteers.Drugs in R&D · 2024Trial
- Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers.Drugs in R&D · 2023Trial
- Targeting neuroplasticity in old brain: restoring synapse with cognitive strategies.Biogerontology · 2026Review
- Novel Insights into the Distribution and Effects of Perfluorooctanesulfonic acid (PFOS) in the Nervous System of a Frog Tadpole Model by Mass Spectrometry Imaging.Environmental science & technology · 2026Article
- Therapeutic and chemopreventive potential of melatonin in liver diseases: targeting oxidative stress and inflammatory signaling.Frontiers in pharmacology · 2026Review
- Development of the Sleeping Pills Receptivity and Involuntariness Scale-6 (SPRIS-6) to Assess Acceptance of Hypnotics Use.Nature and science of sleep · 2025Article
- Multisensory integration, brain plasticity and optogenetics in visual rehabilitation.Frontiers in neurology · 2025Review
- Parametric resonance brain model.Scientific reports · 2024Article
- Effects of Approved Pharmacological Interventions for Insomnia on Mood Disorders: A Systematic Review.Clinical neuropsychiatry · 2024Review
- A Decade of Dedication: Pioneering Perspectives on Neurological Diseases and Mental Illnesses.Biomedicines · 2024Article
- COVID-19-Related Brief Insomnia in a 13-Year-Old Adolescent Girl.Sleep science (Sao Paulo, Brazil) · 2024Article
- Effects of evening smartphone use on sleep and declarative memory consolidation in male adolescents and young adults.Brain communications · 2024Article
- 2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association.Sleep science (Sao Paulo, Brazil) · 2023Review
- Focus on Multidisciplinary Aspects of Sleep Medicine.Brain sciences · 2023Article
- Chronotype and Cardiometabolic Parameters in Patients with Bipolar Disorder: Preliminary Findings.Journal of clinical medicine · 2023Article
- Review on age-related differences in non-visual effects of light: melatonin suppression, circadian phase shift and pupillary light reflex in children to older adults.Journal of physiological anthropology · 2023Review
- Recent Progress in Long-Term Sleep Monitoring Technology.Biosensors · 2023Review
- Melatonin as a Harmonizing Factor of Circadian Rhythms, Neuronal Cell Cycle and Neurogenesis: Additional Arguments for Its Therapeutic Use in Alzheimer's Disease.Current neuropharmacology · 2023Review
- Systems Neuroscience 2021 Top Papers: An Editorial Summary.Brain sciences · 2022Article
- Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.Frontiers in neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin, the major regulator of the sleep/wake cycle, also plays important physiological and pharmacological roles in the control of neuronal plasticity and neuroprotection. Accordingly, the secretion of this hormone reaches the maximal extent during brain development (childhood-adolescence) while it is greatly reduced during aging, a condition associated to altered sleep pattern and reduced neuronal plasticity. Altogether, these properties of melatonin have allowed us to demonstrate in both experimental models and clinical studies the great chronobiotic efficacy and sleep promoting effects of exogenous melatonin. Thus, the prolonged release formulation of melatonin, present as a drug in the pharmaceutical market, has been recently recommended for the treatment of insomnia in over 55 years old subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.